Log In
BCIQ
Print this Print this
 

TD-6450

  Manage Alerts
Collapse Summary General Information
Company Theravance Biopharma Inc.
DescriptionMultivalent HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 4 infection; Treat HCV genotype 1b infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1, 2 or 3 infection
Regulatory Designation
PartnerTrek Therapeutics PBC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today